CN1258365C - Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process - Google Patents
Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process Download PDFInfo
- Publication number
- CN1258365C CN1258365C CN 200410065378 CN200410065378A CN1258365C CN 1258365 C CN1258365 C CN 1258365C CN 200410065378 CN200410065378 CN 200410065378 CN 200410065378 A CN200410065378 A CN 200410065378A CN 1258365 C CN1258365 C CN 1258365C
- Authority
- CN
- China
- Prior art keywords
- radix ginseng
- extraction
- chuanxingol
- ethyl acetate
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 20
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 19
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 18
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000000034 method Methods 0.000 title claims description 23
- 230000008569 process Effects 0.000 title description 3
- 241000208340 Araliaceae Species 0.000 claims abstract description 111
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 111
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 111
- 235000008434 ginseng Nutrition 0.000 claims abstract description 111
- 238000000605 extraction Methods 0.000 claims abstract description 42
- 229930182490 saponin Natural products 0.000 claims abstract description 39
- 150000007949 saponins Chemical class 0.000 claims abstract description 39
- 238000002360 preparation method Methods 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 96
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 89
- 238000002347 injection Methods 0.000 claims description 84
- 239000007924 injection Substances 0.000 claims description 84
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 64
- 239000007788 liquid Substances 0.000 claims description 59
- 239000003814 drug Substances 0.000 claims description 44
- 235000017709 saponins Nutrition 0.000 claims description 43
- 239000002253 acid Substances 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 31
- 229940079593 drug Drugs 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000284 extract Substances 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 25
- 238000010992 reflux Methods 0.000 claims description 23
- 230000006837 decompression Effects 0.000 claims description 16
- 238000004321 preservation Methods 0.000 claims description 16
- 238000004064 recycling Methods 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 13
- 238000012546 transfer Methods 0.000 claims description 13
- 238000002481 ethanol extraction Methods 0.000 claims description 11
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 claims description 9
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 claims description 9
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 claims description 9
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 8
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 8
- 235000014593 oils and fats Nutrition 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 7
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000052 vinegar Substances 0.000 claims description 7
- 235000021419 vinegar Nutrition 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 238000005238 degreasing Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 239000000890 drug combination Substances 0.000 claims description 4
- 239000004531 microgranule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 abstract description 16
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 abstract description 16
- 229940114124 ferulic acid Drugs 0.000 abstract description 16
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 abstract description 16
- 235000001785 ferulic acid Nutrition 0.000 abstract description 16
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 150000007965 phenolic acids Chemical class 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000000302 ischemic effect Effects 0.000 abstract description 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 208000029078 coronary artery disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 abstract 2
- 206010008190 Cerebrovascular accident Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 210000000115 thoracic cavity Anatomy 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 24
- 239000012567 medical material Substances 0.000 description 24
- 239000003182 parenteral nutrition solution Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 230000002490 cerebral effect Effects 0.000 description 19
- 230000017531 blood circulation Effects 0.000 description 15
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 230000002107 myocardial effect Effects 0.000 description 11
- 238000011160 research Methods 0.000 description 11
- 208000031225 myocardial ischemia Diseases 0.000 description 10
- 239000008886 xiangdan Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 244000182022 Salvia sclarea Species 0.000 description 8
- 235000002911 Salvia sclarea Nutrition 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 230000036284 oxygen consumption Effects 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 210000004351 coronary vessel Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 230000036581 peripheral resistance Effects 0.000 description 6
- 150000003333 secondary alcohols Chemical class 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 208000010125 myocardial infarction Diseases 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 206010002660 Anoxia Diseases 0.000 description 4
- 241000976983 Anoxia Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 229920001353 Dextrin Polymers 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000007953 anoxia Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930182494 ginsenoside Natural products 0.000 description 4
- 229940089161 ginsenoside Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 210000003516 pericardium Anatomy 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241001023442 Populus suaveolens Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- RQKFOGXUTRDQPB-UHFFFAOYSA-N hydron;2,3,5,6-tetramethylpyrazine;chloride Chemical compound Cl.CC1=NC(C)=C(C)N=C1C RQKFOGXUTRDQPB-UHFFFAOYSA-N 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 238000007639 printing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- DTGKSKDOIYIVQL-NQMVMOMDSA-N (+)-Borneol Natural products C1C[C@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-NQMVMOMDSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 240000005636 Dryobalanops aromatica Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 206010000891 acute myocardial infarction Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229960000846 camphor Drugs 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical compound N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000002385 vertebral artery Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- UGJAEDFOKNAMQD-DVQDXYAYSA-N (-)-Falcarinol Natural products CCCCCCC\C=C\CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-DVQDXYAYSA-N 0.000 description 1
- UGJAEDFOKNAMQD-MQNTZWLQSA-N (3S,9Z)-1,9-Heptadecadiene-4,6-diyn-3-ol Chemical compound CCCCCCC\C=C/CC#CC#C[C@@H](O)C=C UGJAEDFOKNAMQD-MQNTZWLQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UGJAEDFOKNAMQD-UHFFFAOYSA-N Falcarinol Natural products CCCCCCCC=CCC#CC#CC(O)C=C UGJAEDFOKNAMQD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010093 guan-xin-ning Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- KKAHGGJBKUXDNQ-KRWDZBQOSA-N panaxynol Natural products CCCCCCCC=CC=CCC#C[C@@H](O)C=C KKAHGGJBKUXDNQ-KRWDZBQOSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses medical composition and a preparation method thereof for treating cardiovascular and cerebrovascular diseases. The medical composition is composed of 0.4 to 8 parts of extraction substance (the content measured by ferulic acid is from 33 to 39 %) in the class of chuanxiong rhizome phenolic acid, and 2 to 16 parts of saponin (the content measured by ginseng total saponin is from 50 to 56 %) in ginseng. As shown in experiments, the present invention is used for treating a cardiovascular disease of a thoracic obstruction (a coronary heart disease and angina) blood stagnancy and blood stasis symptom, and an ischemic apoplexy disease, and has an obvious treating effect.
Description
Technical field
The present invention relates to a kind of medicine of preventing and treating cardiovascular and cerebrovascular disease and preparation method thereof, be specially medicine that the effective site of Chinese medicine compound Rhizoma Chuanxiong, Radix Ginseng forms and preparation method thereof.
Background technology
Research data confirms that the water-soluble portion in the Rhizoma Chuanxiong is the chuanxingol acid compounds, has antioxidation, anticoagulant, antithrombotic formation, blood fat reducing, resists myocardial ischemia, function such as microcirculation improvement; Ginsenoside in the Radix Ginseng has the sanguimotor hemodynamics of improvement, blood viscosity lowering, and blood fat reducing improves myocardial ischemia and anoxybiotic function fast.Can play good synergy with these two kinds of extract formula treatment cardiovascular and cerebrovascular diseases.Chinese patent CN1171957A discloses a kind of medicine by Rhizoma Chuanxiong and Radix Ginseng prescription, and it is by the clear paste of Rhizoma Chuanxiong water extract and the clear paste of volatile oil and panaxynol extract, and adjuvant is formed.Yet this preparation method of the present application human has been carried out the extraction test preparation of river of the present invention ginseng injection, and find to have following problem: 1. the extract that this technology obtained is an extractum, can not be used for preparing injection; 2. obtain the production that product can not be used for injection according to this technology, do not reach the regulation of injecting drug use because of its clarity; 3. the Rhizoma Chuanxiong volatile oil composition can not dissolve in preparation, shows that this preparation method can not be used to prepare injection at all; 4. it is 0.21% and 4.39% that thing active ingredient percentage ratio is carried in Rhizoma Chuanxiong water extract that uses this technology and obtained and Radix Ginseng alcohol extraction, far can not reach State Food and Drug Administration and require the Chinese medicine effective ingredient to reach 25% above standard.At present commercially available cardiovascular medicament (as GUANXINNING ZHUSHEYE, SHENMAI ZHUSHEYE) preparation content of effective is low and unstable, because the preparation process level is lower, loss of effective components is more in the medicine, Impurity removal is incomplete, cause its composition complexity, dose-effect relationship between each effective ingredient is unclear, has influenced the stability of product curative effect.
Summary of the invention
The present invention will study a kind of medicine of the control cardiovascular and cerebrovascular disease of mainly being made up of the effective site of Chinese medicine compound Rhizoma Chuanxiong and Radix Ginseng.This medicine had both had the effect of treatment cardiovascular and cerebrovascular disease, had the function of protection cardiovascular and cerebrovascular vessel again, can produce synergy aspect the control cardiovascular and cerebrovascular disease.By the medicine of the inventive method preparation effective component content height not only, and effective ingredient percentage ratio height, Impurity removal is more complete, and product effective site and effective ingredient are quite clear and definite, and quality is easy to control, thereby improves the stability of curative effect of medication.But the present invention includes the preparation method of this medicine industrializing implementation.
For addressing the above problem, the invention provides following technical scheme.
A kind of pharmaceutical composition of preventing and treating cardiovascular and cerebrovascular disease, it is made up of active component and pharmaceutically acceptable carrier, and the weight proportion that it is characterized in that described active component is 0.4～8 part of a chuanxingol acid compounds; 2～16 parts of Radix Ginseng total saponinss; The described pharmaceutical composition weight proportion of active component preferably is 1～4 part of a chuanxingol acid compounds; 2～10 parts of Radix Ginseng total saponinss; The weight proportion of the active component that described pharmaceutical composition is even more ideal is 2 parts of chuanxingol acid compounds; 5 parts of Radix Ginseng total saponinss.In the described pharmaceutical composition, ferulaic acid content is 33-39% in the chuanxingol acid compounds, and ginsenoside Rg1 and Re content are 50-56% in the Radix Ginseng total saponins; The cardiovascular and cerebrovascular disease of its treatment mainly comprises coronary heart disease, angina pectoris and cerebral infarction disease.Described pharmaceutical composition contains pharmaceutically acceptable adjuvant, can make injection, tablet, slow releasing tablet, drop pill, electuary, injectable powder, capsule, microgranule.
The present invention prevents and treats the preparation method of cardiovascular and cerebrovascular vessel medicine, comprises the steps: to get Rhizoma Chuanxiong, with ethanol and/or water extraction; Behind the concentrated extracting solution, place, filter; Get filtrate, transfer pH to 5-7; Use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets the chuanxingol acid compound; Get Radix Ginseng, with ethanol and/or water extraction; Behind the concentrated extracting solution, place, filter; Use the ethyl acetate defat, abandon acetic acid ethyl fluid; Water liquid behind the extracting degreasing is used n-butanol extraction, concentrates n-butanol extracting liquid, gets Radix Ginseng total saponins; 0.4～8 part of chuanxingol acid compound and Radix Ginseng total saponins are 2～16 parts by weight, mix, and make various preparations routinely.
In the preparation method preferably of control cardiovascular and cerebrovascular disease pharmaceutical composition, get Rhizoma Chuanxiong, use the 40-60% ethanol extraction; Behind the concentrated extracting solution, place, filter; Get filtrate, transfer pH to 5.5-6.5; Use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets the chuanxingol acid compound; Get Radix Ginseng, use the 70-90% ethanol extraction; Behind the concentrated extracting solution, place, filter; Use the ethyl acetate defat, abandon acetic acid ethyl fluid; Water liquid behind the extracting degreasing is used n-butanol extraction, concentrates n-butanol extracting liquid, gets Radix Ginseng total saponins; Get 2～10 parts of 1～4 part of chuanxingol acid compound and Radix Ginseng total saponins crude products by weight, mix, make injection, tablet, slow releasing tablet, drop pill, electuary, injectable powder, capsule, microgranule routinely with pharmaceutically acceptable carrier.
Controlling cardiovascular and cerebrovascular disease preparation of drug combination method preferably comprises: get Rhizoma Chuanxiong, with 50% alcohol reflux 3 times, extracted 1.5-2 hour at every turn; Merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g; Cold preservation 24 hours is filtered; Get filtrate and transfer pH to 6.0-6.3, use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets Rhizoma Chuanxiong extract, and wherein ferulaic acid content is 33-39%; Get Radix Ginseng, with 80% alcohol reflux 2 times, each 3 hours; Merge extractive liquid,, decompression recycling ethanol is concentrated into 1ml and is equivalent to the 3g crude drug, and cold preservation is spent the night, and removes the upper strata oils and fats, uses the ethyl acetate defat, discards ethyl acetate liquid, and water liquid n-butanol extraction concentrates butanol extraction liquid, gets Radix Ginseng total saponins; Rhizoma Chuanxiong phenolic acid extract, Radix Ginseng total saponins and after adjuvant mixes add the injection water and are prepared into injection.
The present invention has carried out orthogonal test respectively to Rhizoma Chuanxiong phenolic acid extract, ginsenoside's extraction and purification process.Result of the test shows:
The alcohol extraction ethyl acetate extraction extracting method of Rhizoma Chuanxiong phenolic acid extract of the present invention and traditional handicraft ethanol precipitation twice impurities removing method are relatively, the sample ferulaic acid content that the inventive method makes is higher, and ferulaic acid content accounts for total solid ratio height (table 2), shows that extraction is deimpurity to keep effective components in proportions height simultaneously.With traditional handicraft be ethanol precipitation twice method relatively (table 1), the effective ingredient content of ferulic acid has improved 6 times, the ratio that active ingredient accounts for total solid matters is increased to 35.96% by original 0.39%.
Table 1 extraction and secondary alcohol deposition method sample size are relatively
| Sample | Ferulic acid (μ g/g) |
| Extraction sample secondary alcohol deposition method sample | 730.84 84.39 |
Table 2 extraction accounts for the total solid ratio with secondary alcohol deposition method sample size
| Sample | Ferulic acid (mg/g) | Total solid (mg/g) | Percentage ratio |
| Extraction sample secondary alcohol deposition method sample | 0.73 0.08 | 2.03 20.72 | 35.96％ 0.39％ |
With medicinal liquid pH partial neutral, liquor strength moderate (every 1ml is equivalent to contain crude drug 0.5-3g) extracts 5-7 time in each factor of influence extraction chuanxingol acids composition extraction, and each ethyl acetate consumption is good with 1 times.Result of the test shows: when the medicinal liquid pH value between 5-7, concentration is that every 1ml medicinal liquid is equivalent to contain Rhizoma Chuanxiong crude drug 2g, with equivalent solvent extraction 5 times, the composition extraction ratio that can make Rhizoma Chuanxiong is greater than 90%, the extraction efficiency of the too high or too low equal appreciable impact chuanxingol acids composition of pH value; Its more preferred scheme be the medicinal liquid pH value between 5.5-6.5, be the best especially with pH value 6.0-6.3.
To influencing alcohol extraction ginsenoside's principal element: amount of alcohol, concentration of alcohol, extraction time and extraction time carry out L9 (34) orthogonal test by four factors, three levels.Result of the test shows, and is better with 70-90% ethanol extraction efficient, and its best approach is with 80% alcohol reflux 2 times, each 3 hours; For the first time 10 times of amounts, 8 times of amounts for the second time.
Result of the test shows, adopts above-mentioned process, and the content of gained Radix Ginseng total saponins has improved 1.3 times than the traditional handicraft of secondary precipitate with ethanol, and the ratio that active ingredient accounts for total solid matters is increased to more than 53.92% by original 6.24% and (the results are shown in Table 3).
Table 3 extraction accounts for overall ratio with secondary alcohol method sample size
| Sample | Radix Ginseng total saponins (mg/g) | Total solid (mg/g) | Percentage ratio |
| Extraction sample secondary alcohol deposition method sample | 22.01 10.64 | 40.82 170.37 | 53.92％ 6.24％ |
Compared with prior art, the invention has the advantages that: 1, prescription is more scientific and reasonable, and Radix Ginseng is monarch in the side, strongly invigorating primordial QI, and strengthening the spleen and tonifying the lung, the Fructus Alpiniae Oxyphyllae of calming the nerves, promoting the production of body fluid to quench thirst, pharmacological testing has Antishock function, improves myocardial ischemia and anoxia fast.Rhizoma Chuanxiong is a minister, activating QI to alleviate the depression, promoting blood circulation and stopping pain.Can also suppress smooth muscle contraction, strengthen coronary flow, improve myocardial ischemia.Take a broad view of full side and have tonifying QI to produce body fluid, the effect of blood circulation and channel invigorating.The present invention also uses theory of Chinese medical science and has determined the recipe quantity of each flavour of a drug according to clinical experience.2, this method provides chuanxingol acid extraction purification technique and ginsenoside's extraction and purification process method, obtained the effective component content height by this process, and the high extract of effective ingredient percentage ratio, owing to kept the effective ingredient in the Chinese medicine as much as possible, and controlled the ratio of impurity, make in the prescription dose-effect relationship between effective ingredient clearer, quality is easy to control, thereby has guaranteed the stability of curative effect of medication.But 3, the present invention includes the preparation method of this medicine industrializing implementation.The percentage ratio that its effective ingredient of drug extract that the inventive method obtains accounts for solids reaches State Food and Drug Administration's Chinese medicine and will reach 25% requirement, and, make clarity, the inspection of impurity item, safety testing, assay, the finger printing of preparation test the requirement that all meets the national drug standards by a large amount of tests.
Below be ginseng injection for treating cardiovascular diseases aspect, river of the present invention pharmaceutical research:
The present invention studies show that: river of the present invention ginseng injection has tangible prolongation effect to the time-to-live of white mice normal pressure anoxia enduring; Acute myocardial infarction visceral pericardium electrocardiogram to ligation dog anterior descending coronary causes obviously alleviates the degree that Σ-the ST section is unusual, and the content of Serum LDH and CK is had the trend of minimizing, can reduce ischemic myocardium and account for the percentage rate of flesh whole-heartedly; To the acute myocardial ischemia that ligation rat left coronary artery causes, river of the present invention ginseng injection can improve raising that its ST section J orders; The coronary artery of increasing and aortal blood flow, increase per minute hectogram myocardial flow are arranged, increase cardiac output, reduction total peripheral resistance and coronary resistance, the myocardium coefficient of oxygen utilization effect of raising.
1. experiment material
1.1 river of the present invention ginseng injection: provide by Tianyang Pharmaceutical Co., Ltd., Anhui Prov..Lot number: 030306.Every 10ml uses (hereinafter to be referred as " injection group ") with the direct intravenous injection in water for injection dilution back before the test.
1.2 XIANGDAN ZHUSHEYE: big east, Anhui pharmaceutcal corporation, Ltd provides lot number: 010108.10ml/ props up.
1.3 experimental animal: Kunming kind white mice, Wister rat, rabbit are provided the quality certification by laboratory animal room of this institute: No. 01,02, the real moving accurate word of Anhui doctor.One week of breeding observing before the test.The hybrid dog, male and female dual-purpose, female unpregnancy, body weight 8-13kg, market purchase.
2. experimental technique and result
2.1 to the influence of anoxia enduring time-to-live of white mice normal pressure (chief editor such as Xu Shuyun. pharmacological experimental methodology, Beijing, the People's Health Publisher, second edition in 1991,945-955).
The result: river ginseng injection 0.5mg/kg of the present invention, 1.0mg/kg and 2mg/kg give the white mice tail vein injection, there is tangible prolongation effect time-to-live to the white mice normobaric hypoxia, and strengthen gradually with dosage increasing effect, the effect of XIANGDAN ZHUSHEYE group is a little less than river of the present invention ginseng injection Isodose group, compare with the blank group, significant difference (P＜0.01) is arranged.
2.2 to the ligation coronary artery cause the rat myocardial ischemia influence (Qi Chen chief editor. herbal pharmacology research methodology, Beijing, People's Health Publisher,, 540-543,814 in 1994).The result learns by statistics and handles rank rear in table 4.
The result: behind the rat coronary ligation, myocardial ischemia is sustainable more than 8 hours.0.5 hour electrocardiogram just changes after the ginseng injection administration of river of the present invention; Its high dose group administration after 2.0 hours ECG ST section J point raise and change and model control group P＜0.05 relatively; Wherein the dosage group is suitable with the effect of XIANGDAN ZHUSHEYE high dose group.
2.3 to the Electrocardiographic influence of experimental myocardial infarction dog visceral pericardium (Qi Chen chief editor. herbal pharmacology research methodology, Beijing, People's Health Publisher,, 540-543,814 in 1994).The result carries out the statistical procedures rank rear in Fig. 1.
The acute myocardial infarction that river of the present invention ginseng injection and XIANGDAN ZHUSHEYE cause the ligation coronary artery can obviously improve ST section change on the visceral pericardium electrocardiogram.The model control group animal is along with the unusual ∑ value of the postponement ST section of time changes little; And the unusual ∑ value of ST section reduces gradually after river of the present invention ginseng injection height, middle dosage group and the administration of XIANGDAN ZHUSHEYE group, and its minimizing value and model control group relatively have significant difference.River of the present invention ginseng injection high dose group can reduce the weight of rat myocardial infarction, and the XIANGDAN ZHUSHEYE high dose group has only the minimizing infarcted myocardium to account for the ratio of ventricle.To myocardial infarction rat serum enzyme: XIANGDAN ZHUSHEYE and river of the present invention ginseng injection height, middle dosage group all can reduce CK value, with blank group comparison P＜0.05.
2.4 to the influence of anesthesiaing dog heart blood flowing dynamics (the Qi Chen chief editor. herbal pharmacology research methodology, Beijing, People's Health Publisher,, 540-543,814 in 1994): the results are shown in following table
Table 4. river of the present invention ginseng injection is to the influence (n=6) of dog coronary flow (ml/min), cardiac output (L/min)
| Index | Group | Dosage (mg/kg) | Before the administration | Different time after the administration (min) | ||||||||
| 1 | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 | ||||
| Coronary flow | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 48.36± 8.411 48.31± 16.152 45.78± 17.061 47.52± 22.687 41.45± 7.125 | 48.36± 8.411 51.40± 13.505 48.02± 16.3331 54.24± 23.526 43.46± 5.871 | 49.99± 9.169 55.72± 12.979 52.18± 14.332 56.51± 21.305 46.30± 6.826 | 51.89± 8.015 60.52± 16.728 60.24± 17.608 60.40± 22.019 52.00± 5.466 | 51.60± 7.478 60.83± 16.386 62.12± 17.176 60.78± 21.681 53.77± 5.514 | 49.37± 8.647 61.15± 17.127 60.48± 17.969 59.10± 21.497 54.53± 4.513 | 49.69± 8.625 60.56± 16.973 53.92± 14.583 57.96± 22.473 51.59± 4.248 | 47.04± 8.829 58.29± 17.788 48.71± 15.490 55.48± 22.632 48.76± 5.926 | 48.97± 7.501 54.38± 15.781 46.12± 15.045 51.89± 21.882 44.29± 7.465 | 48.68± 6.865 53.76± 16.311 45.52± 15.435 44.63± 23.146 41.39± 5.909 |
| Cardiac output | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 1.772± 0.312 1.605± 0.453 1.493± 0.636 1.315± 0.316 1.908± 0.396 | 1.745± 0.295 1.927± 0.522 1.611± 0.550 1.472± 0.263 1.870± 0.446 | 1.769± 0.263 1.932± 0.625 1.708± 0.446 1.605± 0.306 1.823± 0.462 | 1.862± 0.328 1.975± 0.620 1.778± 0.473 1.688± 0.267 1.844± 0.351 | 1.833± 0.378 2.044± 0.581 1.819± 0.481 1.746± 0.213 1.920± 0.360 | 1.796± 0.346 2.021± 0.582 1.788± 0.435 1.709± 0.226 1.880± 0.542 | 1.798± 0.375 1.916± 0.580 1.628± 0.422 1.654± 0.353 1.908± 0.432 | 1.760± 0.335 1.854± 0.502 1.608± 0.410 1.773± 0.423 1.928± 0.506 | 1.734± 0.336 1.744± 0.502 1.601± 0.411 1.544± 0.264 1.890± 0.446 | 1.756± 0.358 1.734± 0.504 1.684± 0.515 1.516± 0.278 1.926± 0.500 |
With before the administration relatively: * P＜0.05.
Table 5. river of the present invention ginseng injection is to the influence (n=6) of dog coronary resistance (mmHg/ml/100g/min), total peripheral resistance (dyne .s.cm3)
| Index | Group | Dosage (mg/kg) | Before the administration | Different time after the administration (min) | ||||||||
| 1 | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 | ||||
| Coronary resistance | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 0.517± 0.135 0.581± 0.218 0.627± 0.283 0.613± 0.353 0.654± 0.178 | 0.510± 0.129 0.521± 0.145 0.585± 0.279 0.508± 0.238 0.607± 0.143 | 0.491± 0.134 0.460± 0.149 0.515± 0.208 0.470± 0.199 0.577± 0.164 | 0.478± 0.131 0.417± 0.123 0.441± 0.190 0.434± 0.177 0.510± 0.127 | 0.482± 0.132 0.411± 0.112 0.421± 0.153 0.424± 0.171 0.487± 0.099 | 0.500± 0.135 0.409± 0.110 0.432± 0.154 0.430± 0.167 0.476± 0.101 | 0.491± 0.139 0.412± 0.121 0.477± 0.157 0.441± 0.192 0.506± 0.121 | 0.529± 0.148 0.433± 0.151 0.540± 0.210 0.469± 0.211 0.544± 0.145 | 0.499± 0.131 0.451± 0.139 0.571± 0.235 0.491± 0.195 0.618± 0.214 | 0.498± 0.127 0.460± 0.154 0.582± 0.238 0.574± 0.207 0.647± 0.202 |
| Total peripheral resistance | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 5042.0± 1201.2 5106.1± 2166.0 6068.1± 3363.5 6237.4± 1205.5 4170.6± 834.2 | 5035.1± 1055.4 4116.7± 1246.0 5257.4± 2774.6 5446.1± 1089.9 4220.3± 872.6 | 4880.2± 862.1 4050.4± 1668.8 4632.2± 1627.1 5008.2± 944.5 4365.9± 961.8 | 4780.9± 1207.6 3835.9± 1301.1 4391.6± 1687.8 4689.0± 618.5 4240.0± 667.7 | 4915.9± 1348.4 3646.1± 1149.6 4305.7± 1591.5 4456.8± 596.9 4056.0± 698.6 | 4928.4± 1251.9 3722.8± 1355.0 4310.4± 1523.6 4500.6± 592.3 4216.9± 998.3 | 4887.8± 1318.3 3929.4± 1590.2 4764.7± 1743.6 4678.8± 968.1 4094.9± 868.0 | 5078.8± 1418.6 3969.5± 1360.3 4751.7± 1598.1 4371.0± 759.1 4136.4± 977.5 | 5107.2± 1416.9 4181.6± 1484.8 4761.1± 1601.3 4884.7± 1035.4 4244.3± 1046.2 | 5015.4± 1359.5 4215.1± 1568.9 4640.4± 1778.4 4942.4± 1078.3 4130.6± 1003.2 |
With before the administration relatively: * P＜0.05.XIANGDAN ZHUSHEYE and river of the present invention ginseng injection all have the coronary resistance of reduction and total peripheral resistance effect, no significant difference between the two.
Table 6. river of the present invention ginseng injection is to dog per minute hectogram myocardial flow (ml/100g/min), the exponential influence of myocardial oxygen consumption (n=6)
| Index | Group | Dosage (mg/kg) | Before the administration | Different time after the administration (min) | ||||||||
| 1 | 5 | 10 | 15 | 30 | 45 | 60 | 90 | 120 | ||||
| Every hectogram MBF | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 216.7± 36.97 211.4± 70.62 216.1± 115.45 240.7± 130.77 181.7± 45.98 | 216.7± 36.97 223.6± 57.69 226.4± 112.86 273.0± 137.26 189.8± 40.43 | 224.3± 42.16 244.5± 68.93 243.0± 105.87 283.9± 127.67 202.9± 46.79 | 232.7± 36.36 262.7± 69.47 281.6± 126.92 302.7± 131.65 226.8± 41.92 | 231.4± 35.02 263.8± 67.58 288.7± 125.97 304.7± 130.42 234.1± 40.74 | 221.3± 38.60 264.9± 68.62 281.9± 129.05 296.0± 128.45 236.8± 37.19 | 223.0± 40.71 263.4± 73.22 250.7± 109.74 291.2± 133.17 224.9± 37.91 | 211.3± 40.78 253.3± 72.82 228.1± 108.98 278.8± 133.55 212.4± 39.99 | 220.0± 35.88 235.5± 63.64 216.1± 105.77 260.2± 128.94 194.2± 47.93 | 218.8± 34.29 233.3± 66.90 213.6± 107.40 220.5± 124.12 181.4± 41.43 |
| The myocardial oxygen consumption index | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 165.8± 33.120 155.7± 18.990 178.0± 43.099 182.1± 37.934 176.1± 41.188 | 162.9± 32.866 149.4± 24.576 172.3± 43.550 179.4± 35.432 171.4± 40.301 | 163.7± 37.550 136.7± 19.184 171.8± 43.363 176.7± 34.079 172.4± 43.320 | 162.7± 33.496 134.3± 16.702 167.2± 43.044 171.8± 34.896 172.9± 43.614 | 163.4± 35.509 132.0± 18.378 169.3± 45.970 167.0± 29.888 170.6± 41.641 | 161.8± 33.521 130.2± 19.606 167.6± 47.592 163.0± 28.650 168.3± 41.992 | 159.9± 35.184 127.7± 20.772 164.5± 44.940 160.1± 29.763 165.7± 40.199 | 162.5± 32.343 122.4± 11.018 162.8± 44.544 159.7± 32.296 165.1± 38.433 | 161.1± 31.900 118.5± 11.075 160.5± 43.287 154.2± 30.297 161.0± 35.449 | 160.9± 33.747 116.3± 11.038 156.8± 45.706 148.3± 28.964 158.2± 34.974 |
With before the administration relatively: * P＜0.05
Table 7. river of the present invention ginseng injection is to the influence (n=6) of dog myocardial oxygen consumption (ml/100g/min), myocardium coefficient of oxygen utilization (%)
| Index | Group | Dosage (mg/kg) | Before the administration | Different time after the administration (min) | |
| 40 | 90 | ||||
| Myocardial oxygen consumption | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 14.62±6.139 15.80±7.932 10.29±4.788 14.02±7.938 9.53±4.866 | 12.04±6.770 16.24±14.250 12.35±7.236 19.04±7.921 15.74±3.665 | 14.92±4.052 15.95±12.974 9.99±6.428 13.68±6.927 12.99±4.220 |
| The cardiac muscle coefficient of oxygen utilization | The parenteral solution group is low in the physiological saline control group Clary injection group parenteral solution group high injection liquid group | N.S 2.5ml 1.5 0.75 0.375 | 35.95±10.117 38.22±8.260 26.59±14.623 33.92±3.832 26.42±13.270 | 35.51±21.643 33.79±21.358 29.63±26.098 40.65±14.070 38.07±13.171 | 45.59±16.307 39.31±20.060 32.17±27.495 37.35±18.075 40.53±15.725 |
Compare with the normal saline group: P＞0.05.River of the present invention ginseng injection high dose group has reduction and XIANGDAN ZHUSHEYE that the effect of the myocardial oxygen consumption of increasing rate is arranged, and low dose group has the trend that increases the scheming oxygen consumption in XIANGDAN ZHUSHEYE and the river of the present invention ginseng injection; But statistics there was no significant difference.From above observation index as can be seen: river of the present invention ginseng injection all has the coronary artery of increasing and aortal blood flow, increases per minute hectogram myocardial flow, increases cardiac output, reduces total peripheral resistance and coronary resistance, reduction myocardial oxygen consumption, improves myocardium coefficient of oxygen utilization effect.River of the present invention ginseng injection can prolong the time-to-live of white mice normal pressure anoxia enduring; To the acute myocardial ischemia that ligation rat left coronary artery causes, river of the present invention ginseng injection can improve raising that its ST section J orders; Improve the dog myocardial ischemia that ligation causes, visceral pericardium electrocardiogram ∑-ST value is had tangible minimizing effect, dwindle the scope of myocardial infarction; The coronary artery of increasing and aortal blood flow are arranged, increase per minute hectogram myocardial flow, increase cardiac output, reduce total peripheral resistance and coronary resistance, reduction myocardial oxygen consumption, improve myocardium coefficient of oxygen utilization effect.
Ginseng injection for treating cerebrovascular aspect, river of the present invention pharmaceutical research:
1. give Canis familiaris L. intravenous injection river of the present invention ginseng injection, Canis familiaris L. internal carotid artery blood vessel and vertebral artery blood vessel are had certain dilating effect, can increase per 100 Borneo camphor tissue blood flows amount, reduce cerebral vascular resistance, significant difference is relatively arranged with the blank group; River of the present invention ginseng injection does not all have obvious influence to Sanguis Canitis pressure, heart rate and electrocardiogram.On intraluminal middle cerebral artery occlusion in rats ligation (MCAO) model, river ginseng injection intravenous injection can significantly alleviating cerebral tissue infraction percentage by weight of the present invention, and can obviously improve the MCAO rat behavior and learn index, significantly suppress the rising of MDA content in the MCAO rat cerebral tissue, cyanogen and can significantly suppress the reduction of NO content in the MCAO rat cerebral tissue.
2. test medication: river of the present invention ginseng injection is provided lot number: 030306 by Tianyang Pharmaceutical Co., Ltd., Anhui Prov.; Ligustrazine Hydrochloride Injection: Tianjin gold credit aminoacid company limited is produced lot number: 030322.Chlorination nitro blue tetrazolium (NBT): this (WDSS) biotech firm product, lot number: 30550 are matched in the Ward; Nitric oxide (NO) test kit: Nanjing is built up bio-engineering research and is produced, lot number: 20030115; MDA measures test kit: Nanjing is built up bio-engineering research and is produced, lot number: 20030820; The protein content determination test kit: Nanjing is built up bio-engineering research and is produced, lot number: 20030818.Experimental animal: mongrel, body weight 8.5-13.0kg, male and female dual-purpose, female unpregnancy, market purchasing; SD rat (body weight 210-280g) is provided by Medical University Of Anhui's Experimental Animal Center, the animal quality certification number: real moving accurate No. 01 of Anhui doctor, laboratory rearing temperature: 18 ± 2 ℃;
3. test method: to the influence of anesthetized dog cerebral blood flow; The intraluminal middle cerebral artery occlusion in rats ligation.
4. result of the test:
4.1 river of the present invention ginseng injection, the results are shown in Table 8 and Fig. 2 to the influence of the every 100g of anesthesia Canis familiaris L. cerebral tissue blood flow.
Table 8-l river of the present invention ginseng injection is to the influence (x ± s of the every 100g of anesthesia Canis familiaris L. cerebral tissue blood flow; N=6)
| Group | Dosage (mg.kg -1) | Blood flow (ml.100g.min before the administration -1) | The ml.100g.min of different time cerebral tissue blood flow after the administration -1 | ||
| lmin | 5min | 10min | |||
| Chuanshentong parenteral solution of the present invention is low in the high chuanshentong parenteral solution of the present invention of blank group Ligustrazine Hydrochloride chuanshentong parenteral solution of the present invention | N.S 0.2 2.0 1.0 0.5 | 581.83±150.72 426.91±123.27 557.72±127.26 542.35±141.42 541.06±69.45 | 576.82±154.92 596.51±111.23 608.07±140.62 550.66±147.38 541.06±69.45 | 576.52±164.59 632.26±142.52 * 664.00±146.64 * 576.30±154.78 545.47±67.43 | 585.62±169.17 647.88±106.45 * 671.4l±141.76 * 599.28±165.24 584.40±73.49 |
Compare with the blank group: * P＜0.05, * * P＜0.0l.
Table 8-2 river of the present invention ginseng injection is to the influence (x ± s of the every 100g of anesthesia Canis familiaris L. cerebral tissue blood flow; N=6)
| Group | (the ml.100g.min of different time cerebral tissue blood flow after the administration -1) | |||||
| 15min | 30min | 45min | 60min | 90min | 120min | |
| Chuanshentong parenteral solution of the present invention is low in the high chuanshentong parenteral solution of the present invention of blank group Ligustrazine Hydrochloride chuanshentong parenteral solution of the present invention | 579.44± 164.06 644.23± 123.48 * 668.11± 130.44 * 607.00± 165.55 584.40±73.49 | 582.25± 161.42 612.34± 117.64 648.8l± 131.14 * 602.92± 173.26 560.02±70.37 | 577.25± 154.57 599.34± 106.42 623.32± 137.74 * 584.87± 166.06 543.76±68.01 | 581.72± 150.72 577.32± 124.36 608.79± 131.02 564.27± 165.13 541.06±69.45 | 580.28± 152.40 574.35± 110.23 577.07± 146.88 553.16± 139.55 541.06±69.45 | 580.28± 152.40 565.26± 115.60 557.70± 151.35 542.85± 145.83 541.06±69.45 |
Compare with the blank group:
*P＜0.05,
*P＜0.01.
As can be seen, river of the present invention ginseng injection group can make the every 100g of anesthesia Canis familiaris L. cerebral tissue blood flow increase during 5min after administration, and continues to 15-30min always from table 8 and Fig. 2, with matched group relatively, significant difference.
4.2 the influence (blood pressure is not had obvious effect) that river of the present invention ginseng injection is pressed the anesthesia Sanguis Canitis
4.3 river of the present invention ginseng injection is to the influence of MCAO rat cerebral ischemia derogatory behaviour index
Result and NS group compare, and large, medium and small three the dosage groups of river ginseng injection of the present invention are the same with the positive drug group, all can obviously improve the MCAO rat behavior and learn index.
4.4 river of the present invention ginseng injection is to the influence of MCAO rat cerebral infarction tissue weight
The result: have tangible cerebral infarction to take place behind the rat MCAO, the big or middle dosage group of river ginseng injection of the present invention (iv) can obviously reduce cerebral infarction tissue weight percentage ratio, and its maximal percentage inhibition is 46.4%.
4.5 river of the present invention ginseng injection is to the influence of MCAO rat cerebral tissue biochemical indicator
The result: the big or middle dosage group of river ginseng injection of the present invention can significantly suppress the rising of MDA content in the MCAO rat cerebral tissue, and big or middle dosage can significantly suppress the reduction of NO content in the MCAO rat cerebral tissue.
Intravenous injection river of the present invention ginseng injection has certain dilating effect to Canis familiaris L. internal carotid artery and vertebral artery blood vessel, can increase per 100 Borneo camphor tissue blood flows amount, reduces cerebral vascular resistance, with the blank group significant difference is arranged relatively.River of the present invention ginseng injection does not all have obvious influence to Sanguis Canitis pressure, heart rate and electrocardiogram.Rat MCAO is the animal model of a research cerebral ischemia of using always, and is comparatively approaching with people's cerebrovascular ischemic injuries.This research is found on this model, the intravenous injection of the big or middle dosage group of river ginseng injection of the present invention can significantly alleviate cerebral tissue infraction weight, and large, medium and small three dosage groups all can obviously be improved the MCAO rat behavior and learn index, in addition, the reduction that the big or middle dosage of injection can reduce the content of MDA in the ischemia rat cerebral tissue and can suppress MCAO rat NO content is joined in river of the present invention.The above results prompting river of the present invention ginseng injection has protective effect to ischemic brain injury, can alleviate cerebral tissue infarction percentage by weight, its mechanism may with improve cerebral tissue in NO content, to suppress lipid peroxidation relevant.
Description of drawings
Fig. 1. the experimental myocardial infarction degree of myocardial ischemia of different group dogs (relatively alleviating the % trendgram after the administration with before the administration)
Fig. 2. river of the present invention ginseng injection is to the sketch map of the every 100g of anesthesia Canis familiaris L. per minute cerebral tissue blood flow influence
The specific embodiment
Embodiment one
Get 12 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 50% ethanol (by medical material weight) for the first time with 50% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 50% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 6.2, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 28g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 2 kilograms of Radix Ginsengs, with 80% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 73g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 1.40g, add the dissolving of injection water; Get Radix Ginseng total saponins extract 3.65g, add the dissolving of injection water.Merge above-mentioned two parts solution, be made into 1000 milliliters of medicinal liquids according to a conventional method, filter, fine straining, the inflated with nitrogen embedding, sterilization, check gets totally 200 of 5 milliliters/injections.Using dosage: 10 milliliters/day of intravenous drips, or follow the doctor's advice.
The survey report of river of the present invention ginseng injection is as follows:
The name of an article: river of the present invention ginseng injection; Preparation unit: Tianyang Pharmaceutical Co., Ltd., Anhui Prov.
Test item and result:
Character: this product is flaxen clear liquid; Differentiate: be positive reaction; PH:4.8-6.8; Other: meet requirement under the injection item; Aseptic: qualified; Pyrogen: qualified; Hypersensitive test: qualified; Irritant test: qualified; Hemolytic test: qualified; Ferulaic acid content (pharmacopeia HPLC method): qualified; Radix Ginseng total saponins content (pharmacopeia UV method): qualified; Ginsenoside Rg1, Re content (pharmacopeia HPLC method): qualified; Radix Ginseng finger printing: qualified; Rhizoma Chuanxiong finger printing: qualified.
Embodiment two
Get 12 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 60% ethanol (by medical material weight) for the first time with 60% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 60% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 6.0, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 31g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 2 kilograms of Radix Ginsengs, with 70% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 67g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 1.55g, add the dissolving of injection water; Get Radix Ginseng total saponins extract 3.35g, add the dissolving of injection water.Merge above-mentioned two parts solution, be made into 1000 milliliters of medicinal liquids according to a conventional method, filter, fine straining, the inflated with nitrogen embedding, sterilization, check, check gets totally 200 of 5 milliliters/injections.Using dosage: 10 milliliters/day of intravenous drips, or follow the doctor's advice.
The survey report of river of the present invention ginseng injection meets standards of pharmacopoeia.
Embodiment three
Get 12 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 70% ethanol (by medical material weight) for the first time with 70% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 70% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 6.5, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 26g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 2 kilograms of Radix Ginsengs, with 90% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 66g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 1.30g, Radix Ginseng total saponins extract 3.30g, add an amount of dextrin, mix, wet granulation, after the drying, the encapsulating capsule.Make 198 altogether, each one, twice of every day.
Embodiment four
Get 20 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 50% ethanol (by medical material weight) for the first time with 50% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 50% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 6.3, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 47g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 4 kilograms of Radix Ginsengs, with 80% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 145g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 2.31g, Radix Ginseng total saponins extract 7.27g and mix, make soft material with 60% ethanol with an amount of dextrin, wet granulation, 248g is made in the pack of dry back altogether.Oral each 2g, every day 1 time.
Embodiment five
Get 20 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 50% ethanol (by medical material weight) for the first time with 50% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 50% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 5, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 43g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 4 kilograms of Radix Ginsengs, with 80% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 144g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 2.15g, Radix Ginseng total saponins extract 7.20g and mix, make soft material with 60% ethanol with an amount of dextrin, wet granulation, the pack of dry back is made 246g, oral each 2g, every day 1 time altogether.
Embodiment six
Get 20 kilograms of Rhizoma Chuanxiongs,, add 8 times of amounts of 50% ethanol (by medical material weight) for the first time with 50% alcohol reflux 3 times, extracted 2 hours, second and third time respectively adds 6 times of amounts of 50% ethanol (by medical material weight), reflux, extract, 1.5 hours, merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g, cold preservation 24 hours, filter, get filtrate, transfer pH to 7, with the ethyl acetate extraction of grade (by medical material weight) five times.Merge extractive liquid,, the reclaim under reduced pressure ethyl acetate gets chuanxingol acid compound 42g to the greatest extent, is mainly ferulic acid, carries out ferulic acid HPLC routinely and measures.
Get 4 kilograms of Radix Ginsengs, with 80% alcohol reflux 2 times, each 3 hours; 10 times of amounts (by medical material weight) for the first time, 8 times of amounts for the second time, merging secondary raffinate, decompression recycling ethanol, be concentrated into 1ml and be equivalent to the 3g crude drug, cold preservation is spent the night, and removes the upper strata oils and fats, add and concentrated solution equal-volume ethyl acetate defat three times, discard ethyl acetate liquid, water layer adds and the isopyknic water-saturated n-butanol extraction of water layer 6 times, merges butanol extraction liquid, the reclaim under reduced pressure n-butyl alcohol to the greatest extent Radix Ginseng total saponins 144g, carry out Radix Ginseng total saponins mensuration, ginsenoside Rg1 and Re mensuration routinely.
Get chuanxingol acid compound 2.10 gram, Radix Ginseng total saponins extract 7.20 grams and mix with dextrin in right amount, wet granulation, after the drying, the encapsulating capsule.Make 194 altogether.Each one, once a day.
Claims (9)
1, a kind of pharmaceutical composition of preventing and treating cardiovascular and cerebrovascular disease, it is made up of active component and pharmaceutically acceptable carrier, and the weight proportion that it is characterized in that described active component is 0.4～8 part of a chuanxingol acid compound; 2～16 parts of Radix Ginseng total saponinss; Described chuanxingol acid compound and Radix Ginseng total saponins be preparation as follows respectively:
Get Rhizoma Chuanxiong, with ethanol and water extraction; Behind the concentrated extracting solution, place, filter; Get filtrate, transfer pH to 5-7; Use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets the chuanxingol acid compound;
Get Radix Ginseng, with ethanol and water extraction; Behind the concentrated extracting solution, place, filter; Use the ethyl acetate defat, abandon acetic acid ethyl fluid; Water liquid behind the extracting degreasing is used n-butanol extraction, concentrates n-butanol extracting liquid, gets Radix Ginseng total saponins.
2,, it is characterized in that active component and the weight proportion thereof of making it are: 1～4 part of chuanxingol acid compound according to the described pharmaceutical composition of claim 1; 2～10 parts of Radix Ginseng total saponinss.
3,, it is characterized in that active component and the weight proportion thereof of making it are: 2 parts of chuanxingol acid compounds according to the described pharmaceutical composition of claim 2; 5 parts of Radix Ginseng total saponinss.
4, according to the described pharmaceutical composition of one of claim 1 to 3, ferulaic acid content is 33-39% in its chuanxingol acid compound, and ginsenoside Rg1 and Re content are 50-56% in the Radix Ginseng total saponins.
5,, it is characterized in that described pharmaceutical composition contains pharmaceutically acceptable carrier according to the described pharmaceutical composition of one of claim 1 to 3.
6, according to the described pharmaceutical composition of one of claim 1 to 3, the dosage form that it is characterized in that described pharmaceutical composition is injection, tablet, drop pill, electuary, injectable powder, capsule, microgranule.
7, claim 1 control cardiovascular and cerebrovascular disease preparation of drug combination method comprises the steps:
Get Rhizoma Chuanxiong, with ethanol and water extraction; Behind the concentrated extracting solution, place, filter; Get filtrate, transfer pH to 5-7; Use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets the chuanxingol acid compound;
Get Radix Ginseng, with ethanol and water extraction; Behind the concentrated extracting solution, place, filter; Use the ethyl acetate defat, abandon acetic acid ethyl fluid; Water liquid behind the extracting degreasing is used n-butanol extraction, concentrates n-butanol extracting liquid, gets Radix Ginseng total saponins;
0.4～8 part of chuanxingol acid compound and Radix Ginseng total saponins are 2～16 parts by weight, mix, and make various preparations routinely.
8, by the described cardiovascular and cerebrovascular disease preparation of drug combination method of controlling of claim 7, it is characterized in that:
Get Rhizoma Chuanxiong, use the 40-60% ethanol extraction; Behind the concentrated extracting solution, place, filter; Get filtrate, transfer pH to 5.5-6.5; Use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets the chuanxingol acid compound;
Get Radix Ginseng, use the 70-90% ethanol extraction; Behind the concentrated extracting solution, place, filter; Use the ethyl acetate defat, abandon acetic acid ethyl fluid; Water liquid behind the extracting degreasing is used n-butanol extraction, concentrates n-butanol extracting liquid, gets Radix Ginseng total saponins;
Get 2～10 parts of 1～4 part of chuanxingol acid compound and Radix Ginseng total saponins crude products by weight, mix, make injection, tablet, drop pill, electuary, injectable powder, capsule, microgranule routinely with pharmaceutically acceptable carrier.
9, by the described cardiovascular and cerebrovascular disease preparation of drug combination method of controlling of claim 8, it is characterized in that:
Get Rhizoma Chuanxiong,, extracted 1.5-2 hour at every turn with 50% alcohol reflux 3 times; Merge extractive liquid,, decompression recycling ethanol, adjustment volume extremely every 1ml is equivalent to contain Rhizoma Chuanxiong crude drug 1g; Cold preservation 24 hours is filtered; Get filtrate and transfer pH to 6.0-6.3, use ethyl acetate extraction, concentrated vinegar acetoacetic ester extracting solution gets Rhizoma Chuanxiong extract, and wherein ferulaic acid content is 33-39%;
Get Radix Ginseng, with 80% alcohol reflux 2 times, each 3 hours; Merge extractive liquid,, decompression recycling ethanol is concentrated into 1ml and is equivalent to the 3g crude drug, and cold preservation is spent the night, and removes the upper strata oils and fats, uses the ethyl acetate defat, discards ethyl acetate liquid, and water liquid n-butanol extraction concentrates butanol extraction liquid, gets Radix Ginseng total saponins;
Chuanxingol acid compound, Radix Ginseng total saponins and after carrier mixes add the injection water and are prepared into injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065378 CN1258365C (en) | 2004-11-30 | 2004-11-30 | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410065378 CN1258365C (en) | 2004-11-30 | 2004-11-30 | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1631370A CN1631370A (en) | 2005-06-29 |
| CN1258365C true CN1258365C (en) | 2006-06-07 |
Family
ID=34846480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410065378 Expired - Fee Related CN1258365C (en) | 2004-11-30 | 2004-11-30 | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1258365C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110693929A (en) * | 2019-09-09 | 2020-01-17 | 安徽中医药大学 | Application of compound drug components in the treatment of cerebral infarction recovery period |
-
2004
- 2004-11-30 CN CN 200410065378 patent/CN1258365C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1631370A (en) | 2005-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104815166B (en) | A kind of Chinese medicine composition for treating diabetes and its preparation and application | |
| CN1258365C (en) | Pharmacetutical composition for treating cardiovascular and cerebrovascular disease and its preparing process | |
| CN1291735C (en) | A traditional Chinese medicine dripping pill preparation for promoting blood circulation, removing blood stasis, promoting qi and relieving pain | |
| CN105267889A (en) | Traditional Chinese medicine preparation for treating hyperlipoidemia | |
| CN1182864C (en) | A kind of medicine for treating vascular dementia and its preparation method | |
| CN1775261A (en) | Mingmu-Dihuang preparation and new preparing method | |
| CN102988478B (en) | Traditional Chinese medicine combination for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN102228596B (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
| CN1799582A (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN1045892C (en) | Chinese medicine Guanxintong for preventing and curing coronary heart disease and angina pectoris, and producing process thereof | |
| CN1251745C (en) | Medicine for treating liver and biliary diseases and its preparing method | |
| CN1150918C (en) | Medicine containing active components of Panax japonicum root and preparing process thereof | |
| CN104524235A (en) | Traditional Chinese medicine composition for treating cardiac neurosis | |
| CN1308009C (en) | Health care product having blood pressure regulating function | |
| CN1748748A (en) | Little leaf deervetch herb preparation for pregnant woman and new preparing method | |
| CN1079396A (en) | Intelligence-enhancing pharmaceutical preparation | |
| CN104256618A (en) | Food, health care product or medicine composition with blood sugar reduction function | |
| CN1279961C (en) | Chinese prepared drug formulation for stopping cough and eliminating sputum and its preparation process | |
| CN1810268A (en) | Apoplexy treating medicine composition | |
| CN1692938A (en) | A compound preparation of traditional Chinese medicine for improving eyesight and its preparation method | |
| CN1602949A (en) | Compound capsule for treating meridian wind-phlegm stasis in stroke and preparation method thereof | |
| CN1795901A (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN1899509A (en) | Chinese medicine injection for supplementing qi and recovering pulse and its preparing method | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1973857A (en) | Chinese medicine red sage-astragalus root prepn for treating liver fibrosis and liver cirrhosis and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060607 Termination date: 20091230 |